Arcellx/$ACLX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Arcellx
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
Ticker
$ACLX
Sector
Primary listing
Employees
163
Headquarters
Website
Arcellx Metrics
BasicAdvanced
$5.2B
-
-$3.94
-
-
Price and volume
Market cap
$5.2B
52-week high
$103.66
52-week low
$47.86
Average daily volume
492K
Financial strength
Current ratio
3.987
Quick ratio
3.932
Long term debt to equity
10.056
Total debt to equity
11.751
Interest coverage (TTM)
-12,765.89%
Profitability
EBITDA (TTM)
-235.726
Gross margin (TTM)
-368.45%
Net profit margin (TTM)
-607.01%
Operating margin (TTM)
-675.67%
Effective tax rate (TTM)
-0.71%
Revenue per employee (TTM)
$220,000
Management effectiveness
Return on assets (TTM)
-21.34%
Return on equity (TTM)
-47.18%
Valuation
Price to revenue (TTM)
139.053
Price to book
11.82
Price to tangible book (TTM)
11.82
Price to free cash flow (TTM)
-24.813
Free cash flow yield (TTM)
-4.03%
Free cash flow per share (TTM)
-3.633
Growth
Revenue change (TTM)
-76.96%
Earnings per share change (TTM)
408.68%
3-year earnings per share growth (CAGR)
-16.19%
Bulls say / Bears say
Arcellx reported an adjusted EPS of –$0.99 for Q3, beating the consensus estimate of –$1.06, showing stronger-than-expected control over operational costs (Reuters).
The net loss for Q3 was $55.78 million, less than analysts’ expected loss of $57.33 million, demonstrating improved bottom-line performance despite greater commercial readiness expenses (Reuters).
As of September 30, Arcellx had $576 million in cash and marketable securities, providing operational funding through 2028 to support continued investment in its clinical pipeline (Reuters).
Arcellx’s Q3 collaboration revenue dropped 72% to $4.95 million, missing the analyst consensus of $10.19 million, highlighting a steep decline in partner income after the completion of trial manufacturing (Reuters).
General and administrative expenses climbed in Q3 as the company increased spending for commercial readiness, which compressed margins and widened the year-over-year net loss (Reuters).
Volatile revenue from dependence on collaboration agreements reveals execution risks as Arcellx moves from the development stage to commercialization, with partner revenue exposed to the timing of clinical trials (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 8 Nov 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Arcellx stock?
Arcellx (ACLX) has a market cap of $5.2B as of November 13, 2025.
What is the P/E ratio for Arcellx stock?
The price to earnings (P/E) ratio for Arcellx (ACLX) stock is 0 as of November 13, 2025.
Does Arcellx stock pay dividends?
No, Arcellx (ACLX) stock does not pay dividends to its shareholders as of November 13, 2025.
When is the next Arcellx dividend payment date?
Arcellx (ACLX) stock does not pay dividends to its shareholders.
What is the beta indicator for Arcellx?
Arcellx (ACLX) does not currently have a Beta indicator.